Published in Cell · View the paper (DOI)
Researchers found that SARS-CoV-2 requires the protease TMPRSS2 to enter host cells, a target for therapeutic intervention. The drug camostat mesilate, approved for pancreatic inflammation, shows promise in blocking virus entry into lung cells.
Coverage from 2 institutions
- Preventing spread of SARS coronavirus-2 in humans Deutsches Primatenzentrum (DPZ)/German Primate Center · Mar 5, 2020 · first to report
- Nafamostat is expected to prevent the transmission of new coronavirus infection (COVID-19) The Institute of Medical Science, The University of Tokyo · Mar 30, 2020